Novel Coronavirus Pneumonia (COVID-19)
Conditions
Interventions
control group:conventional treatment
mild ill patients:conventional treatment and ozonated autohemotherapy
severe/critical ill patients:conventional treatment and ozonated autohemotherapy
Sponsors
Tianjin University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) Confirmed patients (or legal guardian) sign a written informed consent form; (2) Aged from 18 to 80 years, male or female; (3) Patients with positive detection of 2019 Novel Coronavirus Pneumonia fluorescence RT-PCR in respiratory specimens or blood samples; (4) Mild ill, severe ill and critical ill patients are grouped based on the fifth edition of the treatment and diagnosis plan published by the National Health Commission of the Peoples Republic of China.
Exclusion criteria
Exclusion criteria: 1) Patients who may be transferred to other hospitals that are not included in the trial within 72 hours; 2) G-6PD defect (Favism); 3) Pregnancy, especially early pregnancy; 4) Patients who continually use immunosuppressant, or are organ transplant recipients within 6 months; 5) Hyperthyroidism; 6) Patients with medical ozone allergy; 7) Patients who are receiving other clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Chest CT;Whole blood cell analysis;Recovery rate;Oxygenation index;Inflammatory response index; | — |
Secondary
| Measure | Time frame |
|---|---|
| Conversion rate of severe patients; | — |
Countries
China
Contacts
Public ContactYu Hongzhi
Haihe hospital, Tianjin University
Outcome results
None listed